Total Payments
$2.3M
2024 Payments
$429,791
Companies
53
Transactions
2,823
Medicare Patients
5,961
Medicare Billing
$2.0M
Payment Breakdown by Category
Other$1.7M (74.5%)
Travel$339,517 (14.5%)
Research$127,123 (5.4%)
Consulting$84,066 (3.6%)
Food & Beverage$47,072 (2.0%)
Education$907.34 (0.0%)
Gifts$42.36 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 490 | 55.1% |
| Honoraria | $453,979 | 212 | 19.3% |
| Travel and Lodging | $339,517 | 1,073 | 14.5% |
| Unspecified | $127,123 | 3 | 5.4% |
| Consulting Fee | $84,066 | 31 | 3.6% |
| Food and Beverage | $47,072 | 987 | 2.0% |
| Education | $907.34 | 24 | 0.0% |
| Grant | $400.00 | 1 | 0.0% |
| Gift | $42.36 | 2 | 0.0% |
Payments by Type
General
$2.2M
2,820 transactions
Research
$127,123
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $524,971 | 606 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $449,574 | 396 | $0 (2024) |
| Amgen Inc. | $370,533 | 476 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $242,235 | 276 | $0 (2019) |
| Aurinia Pharma U.S., Inc. | $182,921 | 268 | $0 (2024) |
| Eli Lilly and Company | $127,123 | 3 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $121,873 | 120 | $0 (2024) |
| Travere Therapeutics, Inc. | $81,119 | 156 | $0 (2024) |
| Vifor Pharma, Inc. | $47,083 | 59 | $0 (2024) |
| Relypsa, Inc. | $46,828 | 86 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $429,791 | 407 | Eli Lilly and Company ($126,511) |
| 2023 | $316,459 | 383 | Horizon Therapeutics plc ($147,223) |
| 2022 | $444,326 | 580 | Horizon Therapeutics plc ($125,596) |
| 2021 | $275,220 | 302 | Mallinckrodt Hospital Products Inc. ($88,850) |
| 2020 | $181,735 | 214 | Mallinckrodt Hospital Products Inc. ($82,728) |
| 2019 | $348,605 | 412 | Mallinckrodt Enterprises LLC ($126,192) |
| 2018 | $197,711 | 254 | Amgen Inc. ($86,234) |
| 2017 | $154,117 | 271 | Mallinckrodt LLC ($50,011) |
All Payment Transactions
2,823 individual payment records from CMS Open Payments — Page 1 of 113
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $134.90 | General |
| 12/21/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | SOBI, INC | — | Consulting Fee | Cash or cash equivalent | $6,743.99 | General |
| 12/19/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,080.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $46.45 | General |
| 12/19/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $41.78 | General |
| 12/19/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $31.00 | General |
| 12/18/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Consulting Fee | Cash or cash equivalent | $5,720.00 | General |
| Category: Nephrology | ||||||
| 12/18/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $5.56 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $1.60 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $22.87 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/11/2024 | Travere Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| 12/11/2024 | Travere Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| 12/11/2024 | Travere Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| 12/11/2024 | Travere Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| 12/11/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/09/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $8.26 | General |
| 12/07/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $69.99 | General |
| Category: Nephrology | ||||||
| 12/07/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $54.98 | General |
| Category: Nephrology | ||||||
| 12/07/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $32.99 | General |
| Category: Nephrology | ||||||
| 12/07/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $23.80 | General |
| Category: Nephrology | ||||||
| 12/06/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Travel and Lodging | In-kind items and services | $513.95 | General |
| Category: Nephrology | ||||||
| 12/06/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Travel and Lodging | In-kind items and services | $292.67 | General |
| Category: Nephrology | ||||||
| 12/05/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $698.25 | General |
| 12/05/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $665.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF RETATRUTIDE (LY3437943) ON RENAL FUNCTION IN PARTICIPANTS WITH OVERWEIGHT OR OBESITY AND CHRONIC KIDNEY DISEASE WITH OR WITHOUT TYPE 2 DIABETES | Eli Lilly and Company | $127,123 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 940 | 27,514 | $2.5M | $535,828 |
| 2022 | 17 | 1,155 | 8,643 | $1.8M | $432,525 |
| 2021 | 21 | 1,679 | 7,531 | $1.9M | $470,377 |
| 2020 | 23 | 2,187 | 6,828 | $2.1M | $547,507 |
Total Patients
5,961
Total Services
50,516
Medicare Billing
$2.0M
Procedure Codes
78
All Medicare Procedures & Services
78 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 91 | 8,760 | $823,057 | $159,076 | 19.3% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 11 | 16,800 | $646,630 | $132,720 | 20.5% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 56 | 191 | $168,197 | $43,953 | 26.1% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 28 | 180 | $158,369 | $41,230 | 26.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 131 | 374 | $134,164 | $34,603 | 25.8% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 33 | 121 | $128,216 | $30,258 | 23.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 122 | 217 | $117,192 | $25,784 | 22.0% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2023 | 45 | 123 | $74,538 | $19,588 | 26.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 134 | 201 | $77,402 | $18,007 | 23.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 102 | 117 | $61,165 | $16,109 | 26.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 17 | 89 | $17,177 | $4,553 | 26.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 56 | 75 | $17,905 | $4,409 | 24.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $10,624 | $2,844 | 26.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 98 | 250 | $17,457 | $2,693 | 15.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 68 | 6,180 | $524,935 | $104,652 | 19.9% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 81 | 282 | $257,748 | $68,260 | 26.5% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 49 | 189 | $209,752 | $53,854 | 25.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 141 | 256 | $144,082 | $35,708 | 24.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 141 | 412 | $129,781 | $33,221 | 25.6% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2022 | 22 | 132 | $120,905 | $30,539 | 25.3% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2022 | 67 | 175 | $110,221 | $29,579 | 26.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 186 | 263 | $105,200 | $26,490 | 25.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 104 | 125 | $76,038 | $19,951 | 26.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 96 | 184 | $40,312 | $10,583 | 26.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 19 | 94 | $20,022 | $5,246 | 26.2% |
About Dr. Abdul Abdellatif, M.D
Dr. Abdul Abdellatif, M.D is a Internal Medicine healthcare provider based in Webster, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1164560595.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Abdul Abdellatif, M.D has received a total of $2.3M in payments from pharmaceutical and medical device companies, with $429,791 received in 2024. These payments were reported across 2,823 transactions from 53 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.3M).
As a Medicare-enrolled provider, Abdellatif has provided services to 5,961 Medicare beneficiaries, totaling 50,516 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 78 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Nephrology
- Location Webster, TX
- Active Since 02/01/2007
- Last Updated 02/02/2026
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1164560595
Products in Payments
- ACTHAR (Biological) $691,809
- KRYSTEXXA (Biological) $638,348
- Parsabiv (Biological) $219,363
- LUPKYNIS (Drug) $182,321
- Kerendia (Drug) $119,098
- Veltassa (Drug) $72,577
- Auryxia (Drug) $46,796
- Parsabiv (Drug) $30,614
- INVOKANA (Drug) $22,541
- JESDUVROQ (Drug) $13,507
- Triferic (Drug) $8,395
- Vafseo (Drug) $6,715
- JYNARQUE (Drug) $5,989
- AURYXIA (Drug) $3,865
- LOKELMA (Drug) $3,859
- FARXIGA (Drug) $3,697
- Renal - HD (Device) $3,433
- Tavneos (Drug) $2,925
- KORSUVA (Drug) $2,194
- Astagraf XL (Drug) $2,140
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Webster
Jose Cuellar Silva, M.d, M.D
Internal Medicine — Payments: $395,286
Internal Medicine $395,286
Regina Pillai, M.d, M.D
Internal Medicine — Payments: $85,013
Internal Medicine $85,013
Ms. Pamela Dugano - Daphnis, Md, MD
Internal Medicine — Payments: $49,018
Internal Medicine $49,018
Abdelnaser Elkhalili, Md, MD
Internal Medicine — Payments: $29,059
Internal Medicine $29,059
Dr. Kenneth Guarnieri, M.d, M.D
Internal Medicine — Payments: $28,177
Internal Medicine $28,177
Samir Mazharuddin
Internal Medicine — Payments: $24,184
Internal Medicine $24,184